Even in this age of technology, researchers have not found any stable method to solve the puzzle of cancer. They are discovering new areas almost every day to ensure a proper solution to this problem. According to a report by the National Cancer Institute, in 2018, 1,735,350 new cases of cancer were diagnosed in the U.S. and approximately, 609,640 people died due to cancer. The statistics of cancer is becoming worse day by day. The report is showing that the growth rate of new cancer cases is 439.2 per 100,000 men and women per year. This has propelled the U.S. government to search for new ways.
FDA, for the second time, has approved a drug to fight cancer. It has given approval to Vitrakvi (larotrectinib) for the treatment of adult and pediatric patients. It will be used to confront with the cancer cells having a specific genetic trait. It will be used to heal solid tumors that have neurotrophic receptor tyrosine kinase (NTRK) gene fusion. TRK fusion is not natural. It happens due to one NTRK gene's abnormal fusion with another gene. Vitrakvi will be used as a weapon to fight against this fusion.
TRK fusion is rare. It does not happen for every cancer case, but the number of cancer patients affected due to this fusion cannot be undermined. Vitrakvi went through three clinical tests. This test included 55 patients who were metastatic and were having TRK gene fusion. Before the approval of Vitrakvi, there was no dedicated and specific solution to this kind of fusion. Vitrakvi ensured 75 percent response rate among different kind of solid tumors. This approval is going to play a vital role in the cancer scenario in the U.S.
A plethora of side effects of the patients has been listed. These side effects include nausea, cough, constipation, diarrhea, dizziness, and vomiting. Healthcare providers have been advised to monitor patients’ liver function regularly. The approval of Vitrakvi is an indication of the fact the FDA will not hesitate to use a drug for eradicating hard diseases. This approval will be helpful for hospitals that were suffering to deal with this issue and will help in their growth.